In the News
- Press Releases
- 2012
- 2011
- 2009
- 2010
- February 2, 2010
- February 26, 2010
- March 3, 2010
- March 3, 2010 Conference Call
- March 5, 2010
- March 8, 2010
- May 4, 2010
- May 6, 2010
- May 7, 2010
- May 11, 2010
- May 11, 2010 Conference Call
- May 13, 2010
- June 24, 2010
- August 6, 2010
- July 29, 2010
- August 3, 2010
- August 3, 2010 Conference Call
- September 7, 2010
- October 26, 2010
- November 2, 2010
- November 5, 2010 Conference Call
- November 5, 2010
- November 11, 2010
- 2008
- Events
- For Media
- Investor Presentations
- Webcasts
Home » In the News » Press Releases » 2010 » February 2, 2010
DUSA Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
|
|
For release at 8:30 a.m.
Contact:
Chad Rubin, Investor Relations Contact, The Trout Group LLC - 646.378.2947
DUSA Pharmaceuticals to Present at the
12th Annual BIO CEO & Investor Conference
WILMINGTON, MASS. – February 2, 2010 — DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 12th Annual BIO CEO & Investor Conference. The conference is being held at the Waldorf Astoria Hotel in New York on February 8-9, 2010. Mr. Doman is scheduled to present at 1:00 p.m. ET on February 9, 2010. Interested parties can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website approximately one hour following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform, and other dermatology products. Levulan® PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face and scalp. DUSA is researching the use of Levulan® PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplant recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH). DUSA also markets other dermatology products, including ClindaReach®. DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.
###